Literature DB >> 18437031

Individual and combined effects of methamphetamine and ketamine on conditioned place preference and NR1 receptor phosphorylation in rats.

D D Xu1, Z X Mo, K K L Yung, Y Yang, A W N Leung.   

Abstract

Methamphetamine (MA), a commonly abused psychostimulant, induces the drug dependence by enhancing the dopamine-mediated neurotransmission. Ketamine (KET) is a non-competitive N-methyl-D-aspartate receptor antagonist, which can be actually mixed with MA for polydrug abuse. In the present study, the individual and combined effects of KET (10 mg/kg, i.p.) and MA (1 mg/kg, i.p.) on conditioned place preference in rats were investigated. The alterations of serine 897 phosphorylations of NR1 receptors in the striatum and ventral tegmental area of after-conditioning rats were measured immunochemically. The results showed repeated administrations of MA, KET and their combination, at the doses studied, all could induce psychological dependences evaluated by conditioned place preference. KET was not able to suppress the MA-induced place preference. The modulations of NR1 phosphorylations in basal ganglia were partly responsible to place preference. Although the alterations induced by KET were not significant in most areas we studied, MA showed a significant increase in the ventral tegmental area but a marked decrease in caudate putamen and nucleus accumbens. Such alterations were much more significant when KET and MA were combined. These results have important implications for public awareness of harm with combined drug abuse. Further investigations toward the specific interaction of the two drugs are necessary. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18437031     DOI: 10.1159/000127492

Source DB:  PubMed          Journal:  Neurosignals        ISSN: 1424-862X


  10 in total

1.  Context-Specific Tolerance and Pharmacological Changes in the Infralimbic Cortex-Nucleus Accumbens Shell Pathway Evoked by Ketamine.

Authors:  Gleice Kelli Silva-Cardoso; Manoel Jorge Nobre
Journal:  Neurochem Res       Date:  2021-03-30       Impact factor: 3.996

2.  Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia.

Authors:  Jana Ruda-Kucerova; Zuzana Babinska; Tibor Stark; Vincenzo Micale
Journal:  Neurotox Res       Date:  2017-04-18       Impact factor: 3.911

Review 3.  The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

Authors:  Justin R Nickell; Kiran B Siripurapu; Ashish Vartak; Peter A Crooks; Linda P Dwoskin
Journal:  Adv Pharmacol       Date:  2014

4.  Behavioral and neurochemical changes induced by repetitive combined treatments of ketamine and amphetamine in mice.

Authors:  Chuan-Ching Lai; Li-Jen Lee; Hsiang-Shu Yin
Journal:  Neurochem Res       Date:  2014-08-19       Impact factor: 3.996

5.  Ketamine sensitization: Influence of dose, environment, social isolation and treatment interval.

Authors:  Keith A Trujillo; Colleen Y Heller
Journal:  Behav Brain Res       Date:  2019-10-05       Impact factor: 3.332

6.  Baclofen facilitates the extinction of methamphetamine-induced conditioned place preference in rats.

Authors:  Robin M Voigt; Amy A Herrold; T Celeste Napier
Journal:  Behav Neurosci       Date:  2011-04       Impact factor: 1.912

7.  NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity.

Authors:  Bo Li; Nino Devidze; Denis Barengolts; Naseem Prostak; Eleana Sphicas; Alfonso J Apicella; Roberto Malinow; Effat S Emamian
Journal:  J Neurosci       Date:  2009-09-23       Impact factor: 6.167

8.  Combining ketamine with astrocytic inhibitor as a potential analgesic strategy for neuropathic pain ketamine, astrocytic inhibitor and pain.

Authors:  Xiao-Peng Mei; Wei Wang; Wen Wang; Chao Zhu; Lei Chen; Ting Zhang; Li-Xian Xu; Sheng-Xi Wu; Yun-Qing Li
Journal:  Mol Pain       Date:  2010-09-06       Impact factor: 3.395

9.  Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; Sairam Krishnamurthy; Seth Norrholm; Gabriela Deaciuc; Kiran B Siripurapu; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2009-10-23       Impact factor: 4.030

10.  Sex- and dose-dependent abuse liability of repeated subanesthetic ketamine in rats.

Authors:  Kristin J Schoepfer; Caroline E Strong; Samantha K Saland; Katherine N Wright; Mohamed Kabbaj
Journal:  Physiol Behav       Date:  2017-10-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.